ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tenecteplase

Also written as “tenecteplase”, “rhTNK-tPA” and “GNR-060”.

Its studies are mostly in Myocardial Infarction · Ischemic Stroke · ST Elevation Myocardial Infarction · Stroke · Heart Arrest, led by 4 companies.

Drug pageTenecteplase: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 9, 200516 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim81 open or runningphase 4since Sep 9, 2005Sep 7, 2005Oct 2, 2027phase 3 · NCT07361302
Hoffmann-La Rocheits history only50 open or runningphase 3since Nov 2, 2006Nov 2, 2006none ahead
CSPC Pharmaceutical Groupits history only21 open or runningphase 4since Jun 12, 2016Jun 12, 2016Sep 30, 2027phase 3 · NCT07201688
AO GENERIUMits history only10 open or runningphase 3since Oct 26, 2022Oct 26, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2005First studies: 2 phase 3 studiesFirst studyNCT00148460, NCT00157261
  2. Sep 9, 2005Phase 4 study in Myocardial InfarctionNCT00168792 · 1,671 enrolled · United States, Austria, Belgium and more
  3. Feb 15, 2008Phase 3 study in Myocardial InfarctionNCT00623623 · 1,899 enrolled · Austria, Belgium, Brazil and more
  4. Jul 2, 20142 phase 3 studies in Myocardial InfarctionNCT02182011, NCT02181985
  5. Jun 4, 2021Phase 3 study in StrokeNCT04915729 · 1,489 enrolled · China
  6. Jan 14, 2026Phase 3 study in Ischemic StrokeNCT07361302 · 1,325 planned · Argentina, Australia, Bulgaria and more

Ahead

  1. Oct 2, 2027Primary completion: phase 3 study in Ischemic StrokeNCT07361302

TargetBeta

PLAT →read by rule
“Tissue-type plasminogen activator exogenous protein”ChEMBL 37, by rule

Studies

All 8 Boehringer Ingelheim leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07361302Ischemic Stroke · Argentina, Australia, Bulgaria and more3RecruitingOct 2, 20271,325
NCT04915729Stroke · China3CompletedOct 8, 20231,489
NCT02182011Myocardial Infarction3CompletedJun 200149
NCT02181985Myocardial Infarction3CompletedApr 20015,989
NCT00623623Myocardial Infarction · Austria, Belgium, Brazil and more3CompletedSep 1, 20121,899
NCT00168792Myocardial Infarction · United States, Austria, Belgium and more4TerminatedJul 20061,671
NCT00157261Heart Arrest · Austria, Belgium, France and more3TerminatedJun 20061,050
NCT00148460Myocardial Infarction · China, Hong Kong, Korea, Republic of3Completed270

How it is read

Names in the registry

  • “tenecteplase”, 6 entries
  • “Tenecteplase”, 5 entries
  • “rhTNK-tPA”, 2 entries
  • “GNR-060”, 1 entry
  • “Full dose TNK-tPA”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.